Online Impact
Statistics from Altmetric.com
ARTICLE USAGE
Cited By
Article Information
Volume 20, Issue 6, pp. 1656-1665
PubMed
Published By
Print ISSN
Online ISSN
History
- Received September 14, 2013
- Revision received December 5, 2013
- Accepted December 21, 2013
- Published first February 3, 2014.
Article Versions
- Previous version (February 3, 2014 - 07:26).
- Previous version (March 5, 2014 - 06:28).
- You are viewing the most recent version of this article.
Copyright & Usage
©2014 American Association for Cancer Research.
Author Information
- Daniel W. Bowles1,
- Jennifer R. Diamond1,
- Elaine T. Lam1,
- Colin D. Weekes1,
- David P. Astling1,
- Ryan T. Anderson1,
- Stephen Leong1,
- Lia Gore1,
- Marileila Varella-Garcia1,
- Brian W. Vogler1,
- Stephen B. Keysar1,
- Elizabeth Freas1,
- Dara L. Aisner2,
- Chen Ren3,
- Aik-Chook Tan1,
- Francois Wilhelm3,
- Manoj Maniar3,
- S. Gail Eckhardt1,
- Wells A. Messersmith1, and
- Antonio Jimeno1
- Authors' Affiliations: 1Department of Medicine, Division of Medical Oncology; 2Department of Pathology, University of Colorado School of Medicine, Aurora, Colorado; and 3Onconova Therapeutics Inc, Newtown, Pennsylvania
- Corresponding Author:
Antonio Jimeno, University of Colorado School of Medicine, MS8117, 12801 East 17th Avenue, Room L18-8101B, Aurora, CO 80045. Phone: 303-724-2478; Fax: 303-724-3892; E-mail: antonio.jimeno{at}ucdenver.edu
March 2014
Volume 20, Issue 6
Volume 20, Issue 6
Phase I Study of Oral Rigosertib (ON 01910.Na), a Dual Inhibitor of the PI3K and Plk1 Pathways, in Adult Patients with Advanced Solid Malignancies
Jump to section
Advertisement